Replies to post #4659 on BioCryst Pharmaceuticals,Inc. (BCRX)

[Deano361]

Yes the analyst forecasts are conservative on sales , and that’s a good thing when we blow them out of water . Sales will be $30-40m/month soon which will raise traders above $20 per share revenue on Bero alone

[Deano361]

We got a pr!! Update on Factor D from the conference:

https://ih.advfn.com/stock-market/NASDAQ/biocryst-pharmaceuticals-BCRX/stock-news/83837811/biocryst-s-oral-factor-d-inhibitor-bcx9930-shows